key: cord-0818242-lrfp3o58
authors: Ahmed, Sakir; Gasparyan, Armen Yuri; Zimba, Olena
title: Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic
date: 2021-01-03
journal: Rheumatol Int
DOI: 10.1007/s00296-020-04764-5
sha: df06e0973655b598f892bd76f21b93d0316a2742
doc_id: 818242
cord_uid: lrfp3o58

Comorbidities in rheumatic and musculoskeletal diseases (RMDs) not only increase morbidity and mortality but also confound disease activity, limit drug usage and increase chances of severe infections or drug-associated adverse effects. Most RMDs lead to accelerated atherosclerosis and variable manifestations of the metabolic syndrome. Literature on COVID-19 in patients with RMDs, and the effects of various comorbidities on COVID-19 was reviewed. The initial data of COVID-19 infections in RMDs have not shown an increased risk for severe disease or the use of different immunosuppression. However, there are some emerging data that patients with RMDs and comorbidities may fare worse. Various meta-analyses have reiterated that pre-existing hypertension, cardiovascular disease, stroke, diabetes, chronic kidney disease, heart failure, lung disease or obesity predispose to increased COVID-19 mortality. All these comorbidities are commonly encountered in the various RMDs. Presence of comorbidities in RMDs pose a greater risk than the RMDs themselves. A risk score based on comorbidities in RMDs should be developed to predict severe COVID-19 and death. Additionally, there should be active management of such comorbidities to mitigate these risks. The pandemic must draw our attention towards, and not away from, comorbidities.

Comorbidities are additional disease states or organ involvement that exist parallel to an index disease, and can delay diagnosis, confound the assessment of disease status, jeopardise treat-to-target strategies and reduce the quality of life or increase mortality [1] . Rheumatic and musculoskeletal diseases (RMDs) are chronic conditions that accrue damage as well as comorbidities over the years. An initiative from the European League Against Rheumatism (EULAR) stresses six significant comorbidities that need to be addressed in RMDs: ischaemic cardiovascular diseases, depression, infections, gastrointestinal diseases, osteoporosis and malignancies [2] .

The most common comorbidity is likely cardiovascular. The risk of a myocardial event is at least 50% higher in patients with rheumatoid arthritis, gout and psoriatic arthritis than for the general population [3] . The risk is also higher for patients with osteoarthritis, and possibly for those with ankylosing spondylitis [3] . In chronic painful conditions like arthritis, there is catastrophising and thus, concomitant depression arising out of such inadept defence mechanisms [4] . Also, the chronic inflammation predisposes to neuroendocrine suppression, fatigue, sarcopenia, osteopenia and possibly a lean variant of the metabolic syndrome ("cachectic obesity") [5] . A meta-analysis has shown that patients with rheumatoid arthritis (RA) are at higher risk for lymphoma and lung malignancies [6] . All these comorbidities including cardiovascular disease, diabetes, osteoporosis, neoplasms, depression, and infections are often sub-optimally diagnosed and managed [2] .

Comorbidities in RMDs have gained an extreme significance as they may be associated with increased risks of hospitalisation and death in the wake of the coronavirus-19 (COVID-19) pandemic. Preliminary data from patients with RMDs in Spain have shown that the presence of comorbidities as well as disease activity were associated with severe COVID-19 and death [7] . The initial cohort of patients with RMDs who had developed COVID-19 in Wuhan, China, included 17 patients, of which at least nine had comorbidities and one of these patients expired. Follow-up interviews of the 16 discharged patients revealed that 10 of them had discontinued or changed their rheumatology drugs [8] . Similarly, the report of the first 600 patients in the COVID-19 Global Rheumatology Alliance (C19-GRA) physicianreported registry also reiterated that age above 65 years and presence of comorbidities were more likely to be hospitalised [9] .

Therefore, it is important to appraise the various comorbidities in RMD in the context of risk for COVID-19, and also, to anticipate how the pandemic influences the management and the prevention of comorbidities in RMDs.

Closely entwined is the question of whether exposure to the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in patients with RMDs would increase the risk of future comorbidities (Fig. 1 ).

Searches were carried out on MEDLINE/PubMed and Scopus in the first week of Oct 2020 for the literature on COVID-19 in RMD patients as per standard recommendations [10] . The common keywords used for the first search were "rheumatic disease", "inflammatory arthritis", "rheumatic and musculoskeletal diseases" in various combinations with "COVID-19" or "SARS-CoV-2". The second search included "COVID-19"or "SARS-CoV-2" with different combinations with "comorbidities", "metabolic syndrome", "diabetes", "hypertension", "lung disease", "cardiovascular disease", "stroke" and "myocardial infarction". The third search used "rheumatic disease", "inflammatory arthritis", or "rheumatic and musculoskeletal diseases" with the different comorbidities keywords included in the second search. The searches were updated in the third week of November to include any articles published since the initial searches. 

In the initial data from China, there were 21 patients with RMDs and length of hospital stay was similar to those without RMDs [11] . A retrospective study from Spain has shown a higher prevalence of hospital diagnosed COVID-19 was more in patients on biologicals but in those on conventional DMARDs [12] . The results are summarised in Table 1 . Telephonic or internet-based surveys estimating the incidence of infection without mentioning comorbidities have not been included in this table. Studies having higher co-morbidities seem to have more severe cases, often attributing it to the presence of RMDs. However, in studies with lower co-morbidities, there appears to be no difference of COVID-19 severity in RMDs and general populations. For patients with RMDs, prior knowledge about avoiding infections may play a role in reducing SARS-CoV-2 infection [13] .

In one of the first retrospective cohorts published from Wuhan, China, almost 50% of patients hospitalised with COVID-19 had comorbidities [36] . In the first 200 patients admitted in New York, the three most common comorbidities were hypertension (76%), hyperlipidemia (46.2%), and diabetes (39.5%) [37] . In an analysis of 3626 patients regarding the effects of race on COVID-19 outcomes, a higher score on the Charlson Comorbidity Index was associated with increased rates of hospitalisation [38] . Thus, comorbidities are common in patients with COVID-19. Table 2 summarises various meta-analyses looking at the associations of multiple comorbidities with mortality or severe disease in COVID-19.

One meta-analysis looking at patients with autoimmune diseases developing COVID-19 found no association with severe disease (3 studies, 1276 patients, OR = 1.21, 95% CI: 0.58-2.50, p = 0.79) or with mortality (3 studies, 835 patients, OR = 1.31, 95% CI: 0.33-5.20, p = 0.95) [56]. However, it should be kept in mind that the RMDs may be only a part of all autoimmune diseases, and the numbers are too small to analysis those with comorbidities.

The different co-morbidities in various RMDs have different prevalence. Patients with difficult to control diseases often have higher comorbidities [57] . The most common comorbidities in each are enumerated in Table 3 . Paediatrics patients often have limited comorbidities, and a systematic review has identified only one single child with RMD who had acquired COVID-19 [58].

Rheumatoid arthritis is associated with most facets of the metabolic syndrome. A meta-analysis has shown that the presence of RA is a risk factor for developing diabetes [97] . The system inflammation in RA, along with the use of glucocorticoids, has been implicated in the development of insulin resistance in RA [98] . This can be closely associated with obesity. At least a quarter of RA patients are overweight (BMI > 25) [62] . Besides being a direct risk factor, it also contributes indirectly by increasing disease activity and making remission more difficult to achieve [99] . Hypertension can be seen in around 50% of RA and is possibly more in patients with resistant disease [57] . Also, underdiagnosis and undertreatment of hypertension and dyslipidaemia in RA are reported [63] . The relationship of psoriatic arthritis with metabolic syndrome is stronger with common mechanistic pathways leading to both [100] . The cardiovascular risks of various rheumatic diseases have been explored in depth in various reviews [101, 102] .

The metabolic syndrome, as well as the pro-inflammatory state, leads to accelerated thrombosis. COVID-19 is intrinsically a pro-thrombotic state [103] . Thus, the risk of thrombosis may be multiplied in the setting of COVID-19.

Amongst lung diseases, interstitial diseases (ILD) have the highest association with rheumatic disease. In RA, it is reported to have a prevalence from 1-60% depending on the methodology used [67] . Many of these patients may not be symptomatic, and only a proportion will have progressive lung disease. However, it is not known whether this will predispose to severe lung COVID-19. ILD are often a major concern in patients with systemic sclerosis (SSc) and with idiopathic inflammatory myopathies (IIM). ILD is the most frequent cause of death in SSc [104] . Registry data show around 40-50% of SSc patients are documented to have ILD [105] . A similar proportion of patients with mixed connective tissue disorder have ILD that is slowly progressive and increases the mortality rate [106] . Also, in the spectrum of IIM, the presence of ILD has been associated with 50% excess mortality [107] . ILD in Sjogren is reported from 8-35% with a 5-year survival of 84% [93, 108, 109] . 

Patients with lupus nephritis may develop chronic kidney damage including interstitial fibrosis and glomerulosclerosis. Similarly, patients with Sjogren and long-standing RA may also develop features of chronic kidney disease (CKD).

A meta-analysis of cohort studies has shown that patients with RA have a higher incidence of developing CKD [110] . Though previously, it was attributable to the high use of nonsteroidal anti-inflammatory drugs, and uncontrolled inflammation (leading to amyloidosis), currently, it is more likely to be associated with accelerated atherosclerosis [111] . Though the mortality in lupus has come down drastically in the last 2 to 3 decades, renal impairment is still seen in up to 40% of patients [85] . Scleroderma renal crisis, though uncommon, is the leading cause of renal transplantation in SSc patients, and 5 years mortality after transplant is 82.5% [112] . It is well known that COVID-19 can directly precipitate acute kidney injury (AKI) and presence of CKD is a poor prognostic marker.

The association between inflammatory rheumatic diseases and depression is well established. A meta-analysis has shown that depression is prevalent in at least one-third of patients with RA [113] . Immunomodulatory therapy seems to improve mental parameters independent of improvement in physical disease activity [114] . Conversely, it is expected that depression would also alter immune parameters in an individual. It can alter the hypothalamic-pituitary-adrenal axis and sympathetic outflow [4] . Depression is associated with immune dysregulation, independent of RMDs [115] . This may predispose to infections and possibly even severe COVID-19. In mice models, it has been shown that repeated social defeat leads to immune suppression [116] . Though there may be a risk of confounding by indication, a cohort of 59,301 people followed up for 14.8 years has shown that those with depression have a higher incidence of blood-stream infections [117] .

RMDs are independently associated with the risk of infections [118] . The various disease-modifying anti-rheumatoid drugs (DMARDs) are immunomodulatory agents. Especially the use of targeted synthetic and biological DMARDs possibly predispose to a higher rate of infections including opportunistic infections [119] . Though rituximab has been implicated to have a higher risk of infections as compared to other biologicals, a meta-analysis has shown no difference [120] .

People with RMDs usually have poorer compliance with vaccination [121] though they are often at increased risks for various infections including pneumococcal, meningococcal, herpetic and other vaccine-preventable infections [122] .

Quantifying the risks for severe COVID-19 and mortality is required. A risk score to predict this will need to include the number of comorbidities providing a weightage score based on the severity and duration of each. The previous history of infections, hypogammaglobulinemia, hospitalisations should also be included in the score. Current immunosuppressive drugs including cumulative exposure to steroids may also be important predictors for severe COVID-19 in the presence of comorbidities [9] . 

Management of hypertension, diabetes and coronary artery disease can help in reducing mortality in COVID-19. Currently, there is ample evidence that the use of angiotensinconverting enzyme (ACE) inhibitors and ACE-receptor blockers in patients with hypertension help in reducing both COVID-19 severity and mortality [123] . A good number of meta-analyses have been carried out looking at the effects of renin-angiotensin inhibitors in COVID-19, and now there is sufficient proof that the use of ACEinhibitors for any indication reduces mortality in COVID-19 [124] . Statins have been shown to be able to reduce cardiovascular mortality in RA [125] . There is a biological basis for statins in reducing atherosclerotic disease in other RMDs like lupus as well [126] . Statins have also been proposed for COVID-19 [127] , and there is emerging evidence that statins can reduce mortality in COVID-19. Analysis of hospital data from China has shown that statin treatment was associated with lower mortality (adjusted hazard ratio of 0.63, 95% CI 0.48-0.84, p = 0.001) compared to non-statin users [128] .

Hydroxychloroquine (HCQS) is a cornerstone drug for lupus and has potential role against atherothrombosis via downregulation of Toll-like receptor signalling, cytokine production, T cell and monocyte activation [129] . Rodent models have demonstrated beneficial effects on endothelial dysfunction [130] . Though not established as a standard of care in vasculitis yet, it has been shown to be helpful in anti-neutrophilic neutrophilic cytoplasmic antibody (ANCA) associated vasculitis, IgA vasculitis, Takayasu's arteritis and polyarteritis nodosa [131] . A significant part of this action may be due to its potential anti-endothelial dysfunction and anti-thrombotic mechanisms in vasculitis. Endothelial dysfunction with 'endotheliitis' plays a significant part in COVID-19 pathogenesis [132] . It has been shown that hydroxychloroquine does not protect from COVID-19 in rheumatology patients [133] . However, higher disease activity in RMDs is independently associated with higher mortality in COVID-19. HCQS should not be stopped in patients already taking them. There is speculation with the demonstration of anti-phospholipid antibodies in COVID-19 patients [134] that these antibodies may have a pathological role. If so, there can be a strong case for HCQS in preventing thrombosis in COVID-19.

Lower vitamin D levels have been associated with more severe COVID-19 [135] . Serum levels of vitamin D have been suggested as a biomarker for outcomes in COVID-19 [136] . The association of mortality with obesity may have low vitamin D as a confounding factor [137] . Many RMDs have low serum vitamin D levels [138] . There is some preliminary evidence of the benefit of vitamin D in RMDs [139] . It needs to be seen whether vitamin D will also help in RMD patients with COVID-19.

Many patients with RMDs receive vitamin D supplementation for osteopenia or osteoporosis. It remains to be seen if this influences the outcomes of COVID-19. One study has shown that people receiving denosumab, zoledronate and duloxetine had a negative association with COVID-19 incidence [140] . This was not true for vitamin D supplementation. It is difficult to interpret the study now and more evidence including the validations of these findings is required.

Maintaining physical health through activity is an essential part of the battle against the pandemic. It is important not to marginalise the benefits of physical activity [137] . Social distancing should not mean any patient has to be isolated at home without any activity like walking. Even staying at home, there is scope for introducing interventions like resistance training, respiratory muscle training (including deep breathing exercises) with aerobics wherever feasible [141] . The breathing exercises described as a part of Yoga may help both respiratory muscles as well have short-term favourable outcomes on depression [142] .

There are case reports of several new rheumatic diseases being diagnosed after SARS-CoV-2 infection. Some may be atypical features of COVID-19 itself while others might be simmering RMDs unmasked during the inflammation of COVID-19. However, COVID-19 may itself also initiate autoimmune diseases including RMDs [143] . One immunemediated syndrome is Multisystem inflammatory syndrome in children (MIS-C) [144] . The inflammatory pathways involved in COVID-19 have remarkable overlap with those of rheumatoid arthritis [145] . However, COVID-19 has not been shown to precipitate arthritis except case reports [146, 147] that are possibly the exceptions that prove the rule. Similarly, there is little evidence to suggest that COVID-19 can worsen pre-existing arthritis [148] .

COVID-19 has been shown to precipitate cardiomyopathy, and lung fibrosis had may have more tremendous implications for patients pre-existing RMDs. Magnetic resonance imaging of patients recovered from COVID-19 has shown active cardiac involvement in 60%, independent of pre-existing conditions and severity of COVID-19 [149] . A similar study had also been reported from China [150] . Post-COVID-19 pulmonary fibrosis is likely to be associated with older age, the severity of pneumonia, and background lung disease [151] . Patients with RMDs predisposing to lung pathology may have higher risks of post-COVID-19 fibrosis.

In data from Switzerland, there was no increase in disease activity of RMDs in the short term since the onset of the pandemic. However, drug non-compliance has increased [152] . This might lead to increased flares in the near future. This can also increase the inflammatory burden and add to cardiovascular risks. Thus, patients with RMDs may have an increased risk of developing comorbidities after exposure to SARS-CoV-2.

The pandemic has forced an unprecedented shift to online platforms and virtual consultations. Now patient-reported outcomes have taken antecedence over physician assessments [153] . However, these will focus more on the primary manifestations of diseases and are likely to relegate comorbidities to the background. Comorbidities, already being sub-optimally managed [2] , maybe neglected further. Newer comorbidities may be missed on teleconsultations.

Many drugs used in rheumatology have been proposed for COVID-19 [154] . However, these have not shown any evidence of benefit to date [155] . The small benefit of these drugs may be offset by the presence of the various comorbidities in RMDs. Thus, unless comorbidities are addressed, we may be missing out on much relevant information.

Again, the pandemic may influence drug compliance due to unavailability of drugs, missing appointments with rheumatologists, or even just a fear of using 'immunosuppressant' drugs. This itself might lead to flares and increased comorbidities that might be attributed as a direct pathobiological effect of COVID-19 [156] .

Thus, there is a need to stratify RMDs as per the presence and number of comorbidities. This will help physicians predict risk for severe COVID-19 as well as future overall outcomes. It may also have implications on prioritising candidates for future COVID-19 vaccines.

The knowledge about various comorbidities and how to tackle these has expanded in the last couple of decades, but the current pandemic threatens to take the focus away. It is crucial to incorporate protocols to address them during consultations, particularly teleconsultations. Holistic management will only be possible when we focus on the patients as a whole, and not just what is mandated by the primary disease targets.

Author contributions Conceptualisation: AS, AYG, and OZ. Methodology: AS and OZ. Writing-original draft: AS and AYG. Writingreview and editing: AS, OZ, and AYG. All the authors have approved the final manuscript and take full responsibility for the integrity of the data and the contents of the manuscript. 

Comorbidity indices

Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative

Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis

Pain, catastrophizing, and depression in the rheumatic diseases

The brain and immune system prompt energy shortage in chronic inflammation and ageing

Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis

Determinants of COVID-19 disease severity in patients with underlying rheumatic disease

New data emerging on outcomes for patients with COVID-19 and rheumatic diseases

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors

Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China

Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic?

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot

Obesity in psoriatic arthritis: comparative prevalence and associated factors

Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis

Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study

Prevalence and type II diabetes-associated factors in psoriatic arthritis

Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease

Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. RMD Open 6:e001364

Patterns of comorbidity and disease characteristics among patients with ankylosing spondylitis-a cross-sectional study

Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study

Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study

Aortic regurgitation is common in ankylosing spondylitis: time for routine echocardiography evaluation?

The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study

What is damaging the kidney in lupus nephritis?

Systemic lupus erythematosus and hypertension

Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study

Coronary artery disease in systemic lupus: a case-controlled angiographic study

Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease

Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis

Renal involvement in primary Sjogren's syndrome: a prospective cohort study

Interstitial lung disease in primary Sjögren's syndrome

Interstital lung disease in ANCA vasculitis

End-stage renal disease in ANCA-associated vasculitis

The presentation and management of hypertension in a large cohort of Takayasu arteritis

Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis

Rheumatoid arthritis, insulin resistance, and diabetes

Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis

Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms

Cardiorheumatology: cardiac involvement in systemic rheumatic disease

Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians

Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad

Interstitial lung disease in systemic sclerosis: current and future treatment

Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group

Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study

Idiopathic inflammatory myopathies and the lung

Quantitative assessment of interstitial lung disease in Sjögren's syndrome

Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: a systematic review from the Italian Society of Rheumatology

Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies

Renal manifestations of rheumatoid arthritis

Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study

The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis

Rheumatoid arthritis and depression: an inflammatory perspective

Immune suppression and immune activation in depression

Alterations of the innate immune system in susceptibility and resilience after social defeat stress

Anxiety and depression symptoms in a general population and future risk of bloodstream infection: the HUNT study

Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study

Opportunistic infections in biological therapy, risk and prevention

Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis

Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Effect of Renin-Angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients

A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis

Should all patients with systemic lupus erythematosus receive cardioprotection with statins?

Potential role of statins in COVID-19

In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19

Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus

Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction

New use for an old treatment: hydroxychloroquine as a potential treatment for systemic vasculitis

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19)

Vitamin-D and COVID-19: do deficient risk a poorer outcome

Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med

Fly AD (2020) Considerations for obesity, vitamin D, and physical activity amid the COVID-19 pandemic

Vitamin D and rheumatic diseases

Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: a systematic review and meta-analysis. Medicine (Baltimore) 96:e7024

Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions

Physical activity and nutrition guidelines to help with the fight against COVID-19

Yoga for depression: a systematic review and meta-analysis

Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment

Autoimmune and inflammatory diseases following COVID-19

COVID-19 revisiting inflammatory pathways of arthritis

The first reactive arthritis case associated with COVID-19

Reactive arthritis after COVID-19 infection. RMD Open 6:e001350

COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and DMARDs on clinical outcomes

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Cardiac involvement in patients recovered from COVID-19 identified using magnetic resonance imaging

Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort

Should we be using the Covid-19 outbreak to prompt us to transform our rheumatology service delivery in the technology age?

Perspectives of immune therapy in coronavirus disease 2019

Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence